ClinicalTrials.gg
Status unknownNCT02251847Updated Sep 29, 2014

The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

A Phase 3 interventional study of Rosuvastatin/Ezetimibe in Hypercholesterolemia, sponsored by IlDong Pharmaceutical Co Ltd. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Planned enrollment
22nd of 57
400 · median 203
Started
2014
with 2 others
Phase 3
33 of 59
none open now
Registered
43rd of 59
by date

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 22nd largest by planned enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2014, is one of 33 in phase 3, and was the 43rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Read the detailed description

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • cholesterol
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypercholesterolemic patient

Exclusion criteria

Exclusion Criteria:

  • Has history of to HMG-CoA reductase inhibitor and Ezetimibe
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    R5

    Rosuvastatin 5mg

    Drug: Rosuvastatin/Ezetimibe

  • Active comparator
    R10

    Rosuvastatin 10mg

    Drug: Rosuvastatin/Ezetimibe

  • Active comparator
    R20

    Rosuvastatin 20mg

    Drug: Rosuvastatin/Ezetimibe

  • Experimental
    R5/E10

    Rosuvastatin 5mg/ezetimibe 10mg

    Drug: Rosuvastatin/Ezetimibe

  • Experimental
    R10/E10

    Rosuvastatin 10mg/ezetimibe 10mg

    Drug: Rosuvastatin/Ezetimibe

  • Experimental
    R20/E10

    Rosuvastatin 20mg/ezetimibe 10mg

    Drug: Rosuvastatin/Ezetimibe

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 8 week in LDL-Cholesterol

    Time frame: baseline and 8 week

Secondary outcomes

  1. Percent change from baseline to 4 week in LDL-Cholesterol

    Time frame: baseline and 4 week

07

Study locations

1 of 1 sites recruiting
  • Gil Medical Center
    Seoul, Korea, Republic of
    Recruiting
    • Tae Hoon Ahn · Contact
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014 and a primary completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
Start
Jul 2014
Primary completionEst.
Jul 2015
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02251847
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Jul 2014
Primary completion
Jul 2015 (estimated)
Last update
Sep 29, 2014

Study contacts

Min-Hee Kwon
Contact
minhee@ildong.com
02-526-3379
Tae Hoon Ahn
principal investigator · Gachon University Gil Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion